y that could be even bigger. The IP exclusivity could potentially be enjoyed by Veru up to 2036 from the Tamsulosin franchise that it licensed from Ariana Therapeutics. Ariana (now Camargo) would receive $10M over three years after the drug has been in market for one year. Tamsulosin XR and DRS would be addressing